Iobenguane I-123 clinical trials

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

This study looks at combining existing treatments for high-risk neuroblastoma to see if it works better. It's for children and young people who have already had intensive therapy, to help prevent the cancer from coming back.